abstract OBJECTIVES: To examine the relationship of cardiac biomarkers with postoperative acute kidney injury (AKI) among pediatric patients undergoing cardiac surgery.
WHAT'S KNOWN ON THIS SUBJECT: Acute kidney injury (AKI) occurs in up to 50% of children after cardiopulmonary bypass and is associated with adverse outcomes. Renal biomarkers have been shown to predict postoperative AKI, but few studies have examined cardiac biomarkers for risk classification.
WHAT THIS STUDY ADDS:
Preoperative levels of creatine kinase-MB and heart-type fatty acid binding protein are strongly associated with the development of postoperative AKI after pediatric cardiac surgery and can be used to improve preoperative clinical risk prediction.
Acute kidney injury (AKI) occurs in up to 50% of children after cardiopulmonary bypass (CPB), 1, 2 and is independently associated with adverse outcomes, including longer lengths of stay (LOSs), prolonged mechanical ventilation, and higher mortality. 3, 4 Early identification of patients at risk for developing AKI may allow implementation of strategies to reduce related morbidity and mortality. 5, 6 Preliminary evidence suggests that biomarkers can help to identify patients at risk for postoperative AKI. 2 In both pediatric and adult populations, renal biomarkers, such as serum cystatin C and neutrophil gelatinase-associated lipocalin (NGAL), have been shown to predict postoperative AKI and improve risk classification when combined with other clinical models. [7] [8] [9] [10] [11] In addition, studies in adults have shown that pre-and postoperative levels of cardiac biomarkers, such as B-type natriuretic peptide (BNP), strongly predict postoperative AKI risk. 12 Only 2 studies in children have examined the prognostic value of BNP on postoperative AKI. 13, 14 Both found that although BNP was not an independent predictor of AKI, it was associated with longer intubation times and higher postoperative mortality. To our knowledge, no studies have examined other cardiac biomarkers, such as troponins, creatine kinase-MB (CK-MB), or heart-type fatty acid binding protein (h-FABP), in children or adults. Preoperative elevations in cardiac biomarkers may reflect the severity of the underlying heart disease, 15 whereas postoperative levels of cardiac biomarkers reflect the complexity of the surgery and the degree of intraoperative cardiac damage, which can increase patients' risk of postoperative complications, such as AKI.
The purpose of this study was twofold. First we evaluated the prognostic utility of 5 cardiac biomarkers (N-type [NT] pro-BNP, CK-MB, h-FABP, high-sensitivity cardiac troponin T [hs-cTnT], and cardiac troponin I [cTnI]), measured preoperatively and immediately after surgery in children, to predict postoperative AKI risk and LOS. We then determined whether these biomarkers provided additional benefit for predicting AKI above that afforded by clinical models.
METHODS

Data from the Translational Research
Investigating Biomarker Endpoints in Acute Kidney Injury consortium study (TRIBE-AKI) were used for these analyses. 16, 17 In brief, this translational study was designed to validate novel kidney injury biomarkers by using a prospective cohort design with serial sample collections on 3 consecutive days. Participants included children aged 1 month to 18 years undergoing cardiac surgery at 3 academic hospitals. To increase the number of children at risk for AKI, we oversampled children undergoing risk adjustment of congenital heart surgery-1 (RACHS-1) category $2 surgeries. Children were recruited preoperatively and followed postoperatively until discharge (n = 319). Institutional review board approval was obtained at each participating center, and all patients provided written informed consent. To capture cardiac biomarker kinetics around the time of cardiac surgery, only patients with a full set of pre-and postoperative samples were included (n = 106). Subject selection was not based on any clinical criteria.
Data Collection
Data on patient demographics and medical history were recorded before surgery. Details about the surgical procedure (eg, type of cardiac abnormality, procedure, bypass time, elective or urgent, and severity) were obtained from the medical record by using standardized definitions of the Society of Thoracic Surgeons data collection tool. Severity of condition and surgical risk were evaluated using the RACHS-1 method. 18, 19 Venous blood samples were collected preoperatively, within 6 hours after surgery, and on postoperative days 2 and 3. Blood was collected in EDTA tubes and centrifuged to separate plasma, divided into bar-coded 0.5-mL cryovials, and stored at -80°C. One vial from each time-point was used for biomarker measurements with a single freeze-thaw. Biomarkers were measured with a Roche automated analyzer (Roche Elecsys 2010; Roche Diagnostics, Basel, Switzerland) for NT pro-BNP (pmol/L) (coefficient of variation [CV] range 3.6%-7.7%) and hs-cTnT (ng/L) (CV range 2.5%-10.5%), the Beckman Coulter Access II instrument (Beckman Coulter, Brea, CA) for the AccuTnI assay cTnI (µg/L) (CV range 5.4%-20%) and CK-MB (µg/L) (CV range 2.7%-8.2%), and the Evidence Investigator Cytokine Custom Array (Randox Crumlin, United Kingdom) for h-FABP (µg/L) (CV 17%). Preoperative serum creatinine (SCr) was measured as part of routine clinical care using modified Jaffe or enzymatic assays, and preoperative glomerular filtration rates (GFRs) were estimated by using the Schwartz equation.
Outcome Definition
The primary outcome in this study was development of AKI, which was defined as rise in SCr of $50% or 0.3 mg/dL from preoperative baseline within the first 7 days after surgery. Severe AKI was defined as either a doubling of creatinine or dialysis requirement. [20] [21] [22] Secondary outcomes included in-hospital mortality, hospital and intensive care unit (ICU) LOS, and time to extubation. [27] [28] [29] [30] [31] [32] We then evaluated the association between these biomarkers with ICU and hospital LOS by using logistic regression. ICU and hospital stays were dichotomized by using the median value of each (3 days for ICU stay and 7 days for hospital stay) to quantify the relation between elevations in cardiac biomarkers and risk of prolonged hospitalization by using risk measures. Models were adjusted for patient and clinical characteristics as well as AKI status to determine whether AKI explained the longer LOS in patients with high cardiac biomarker values. 57 (51) 46 (41) 61 (40) . with mild or no AKI. Only 2 deaths occurred in-hospital, both among patients with severe AKI.
Statistical Analyses
RESULTS
Of
The trajectories of the 5 cardiac biomarkers during the first 3 days of hospitalization stratified by AKI status are displayed in Fig 1. Markers of cardiac injury (CK-MB, h-FABP, cTnI, and hs-cTnT) peaked within 6 hours after surgery, whereas markers of cardiac function (NT pro-BNP) peaked on day 2. Across all 4 time-points, median levels of cardiac biomarkers were higher among patients who developed severe AKI compared with mild or no AKI.
Preoperative Cardiac Biomarkers by AKI status. There were significant differences across AKI groups in preoperative CK-MB, hs-cTnT, and h-FABP levels (P = .001, P = .048, and P , .001, respectively), but preoperative levels of NT pro-BNP and cTnI were comparable across groups (P = .2 and P = .3, respectively).
Higher preoperative levels of CK-MB and h-FABP were associated with higher crude odds of developing AKI ( Table 2 ). After adjustment for patient characteristics, the association of preoperative CK-MB and h-FABP with development of postoperative AKI remained significant. A 1-unit increase in log CK-MB was associated with a fivefold increase in the odds of developing AKI after surgery. Similarly, a 1-unit increase in log h-FABP was associated with a threefold increase in the odds of developing AKI. No other preoperative biomarkers were associated with the development of AKI after adjustment for patient characteristics (all P . .1).
ROC analyses revealed preoperative CK-MB and h-FABP to be candidate biomarkers with high discriminatory value for predicting AKI (Fig 3 A  and B Median biomarker values by AKI group collected preoperatively and 0 to 6 hours, 2 days, and 3 days after surgery.
the clinical model (P = .60 and P = .51, respectively); however, both biomarkers were associated with significant NRI and IDI values ( Table 4 ). Given that changes in the AUC are insensitive when comparing nested models, it is not surprising that preoperative CK-MB and h-FABP added significant discriminative value to the clinical model when assessed by NRI and IDI, but increased the AUC only slightly in ROC analyses. The optimal cutoff for detecting postoperative AKI was 2.9 µg/L (sensitivity 64.2%, specificity 64.6%) for preoperative CK-MB and 2.6 pg/mL (sensitivity 68%, specificity 68.8%) for preoperative h-FABP (Table 5 ).
Secondary analyses showed that higher preoperative hs-cTnT, CK-MB, and h-FABP were associated with longer ICU and hospital stays independent of AKI status (Table 6) . Preoperative NT pro-BNP and cTnI were associated with longer ICU but not hospital stays. Of the 5 preoperative biomarkers tested, CK-MB and h-FABP exhibited the strongest association with LOS.
Postoperative Day 1 Cardiac Biomarkers
Biomarker distributions on postoperative day 1 are presented in Fig 4. Median levels of biomarkers differed significantly across AKI groups for all biomarkers except CK-MB (P , .05 for NT pro-BNP, cTnI, hs-cTnT, and h-FABP). In unadjusted analyses, only postoperative hs-cTnT was borderline associated with the development of AKI, but adjustment for patient and operative characteristics attenuated this relationships ( Table 2 ). All 5 biomarkers were nonsignificant in multivariable analyses.
Postoperative hs-cTnT yielded the highest AUC for predicting AKI in both unadjusted and adjusted ROC analyses (Fig 3C) . When used alone, postoperative hs-cTnT had a moderately high AUC (0.62, 95% CI 0.51-0.73), but addition of hs-cTnT
FIGURE 2
Distribution of serum values of preoperative cardiac biomarkers by AKI status.
to the clinical model did not significantly improve the AUC of the clinical model (P = .74) (Table 3) . Similarly, neither the NRI nor IDI proved significant for hs-cTnT or any other postoperative biomarkers (all P . .05) ( Table 4) .
In secondary analyses, higher postoperative levels of NT pro-BNP predicted longer ICU and hospital LOS, which persisted even after adjustment for AKI status (Table 6 ).
Postoperative hs-cTnT and h-FABP also were associated with increased ICU but not hospital stay.
DISCUSSION
In this multicenter, prospective study of pediatric patients undergoing cardiac surgery for congenital conditions, we found that preoperative CK-MB and h-FABP were strong and independent predictors of postoperative AKI. A 1-unit increase in preoperative log CK-MB was associated with a fivefold increase in the odds of AKI, and a 1-unit elevation in preoperative log h-FABP increased the odds of developing AKI by 3 times. We found that a single measurement of each of these biomarkers provided good discrimination between patients who developed AKI and those who did not when used alone and in combination with clinical models. Our study expands the current literature by examining additional cardiac biomarkers in the prediction of AKI, including markers of cardiac function (NT pro-BNP) and cardiac injury (cTnI, hs-cTnT, CK-MB, and h-FABP). In our study, preoperative CK-MB and h-FABP outperformed NT pro-BNP in predicting postoperative AKI as assessed by larger odds ratios and higher AUCs. We also found that higher preoperative levels of CK-MB and h-FABP were associated with extended ICU and hospital LOS in addition to AKI, which is consistent with previous studies. [46] [47] [48] [49] However, addition of AKI to these models did not attenuate the risk ratios, suggesting that the relationship between these biomarkers and extended LOS is mediated by factors other than AKI. These findings suggest that CK-MB and h-FABP may be superior to BNP in evaluating risk of postoperative AKI in children.
Several mechanisms may explain the relationship between preoperative CK-MB and h-FABP with postoperative AKI. In children with congenital heart disease, elevations in CK-MB and h-FABP are most likely released from damaged myocardium, suggesting that patients with higher preoperative levels may have more severe underlying cardiac disease. 50 These patients may have reduced cardiac reserve at baseline and may be at higher risk of hemodynamic instability in the perioperative setting, which may place them at greater risk of postsurgical complications, including AKI. Additionally, patients with more severe baseline disease may require longer cross-clamping and CPB times, which can independently increase the risk of postoperative AKI. 16 Although the proposed mechanisms are plausible, our data showed mixed results for several of these explanations. For example, neither cross-clamping nor CPB duration was associated with postoperative AKI in our sample. Additionally, it is unclear why only 2 markers of cardiac injury (CK-MB and h-FABP) predicted AKI but not preoperative cardiac troponins. One potential explanation is the large number of children with undetectable levels of preoperative cTnI (n = 55) and hs-cTnT (n = 38). Even with low levels of cardiac damage, the range of cardiac troponin values may not have been wide enough to detect subtle differences between children who developed postoperative AKI and those who did not. In fact, previous studies also have shown that cardiac troponin levels are often undetectable in children with congenital heart abnormalities or other cardiac diseases such as Kawasaki, [51] [52] [53] but CK-MB levels are frequently elevated and vary by severity and type of cardiac defect. 50, 54 Thus, it is possible that the kinetics of the cardiac troponins, CK-MB, and h-FABP differ in children.
The high performance of CK-MB and h-FABP in our study may be partly explained by the fact that we limited our sample to only higher-risk patients undergoing complex cardiac surgeries. Larger studies are needed to replicate our findings in patients with varying levels of surgical risk and to determine the costeffectiveness of monitoring CK-MB and h-FABP preoperatively. Recently, the concept of a renal angina index has been proposed to direct biomarker assessment in noncardiac ICU patients who meet a certain level of risk and demonstrate signs of evolving AKI. 55, 56 This concept has arisen due to concerns that widespread diagnostic testing may yield high numbers of false-positive results. 57 In the cardiac surgery setting, a similar parallel would be clinical risk scores. In TRIBE-AKI, we found that using a simple baseline clinical risk model, including age, gender, RACHS-1 category, preoperative eGFR percentile, CPB time, and study site, predicted postoperative AKI with AUC 0.77 and was improved by adding biomarkers to this model. 36 Similar risk models may help to increase the specificity and positive predictive value of biomarker screening tests. 58 Before the use of these biomarkers can be incorporated into routine clinical practice, however, AKI prevention strategies must be have confounded the relationship between cardiac biomarkers and postoperative AKI. Nevertheless, we adjusted for RACHS-1 category as an overall assessment of preoperative illness severity. Fifth, neonates were excluded from this study because previous studies have shown that using SCr to diagnose AKI in neonates can be problematic. 59 Neonates have higher baseline levels of SCr at birth, which gradually decline during the first few weeks of life due to ongoing renal functional development. 60, 61 These changes, combined with the lower muscle mass in neonates, make it difficult to interpret changes in SCr with AKI. Thus, our findings are not generalizable to children ,1 year of age, and future multicenter studies should be performed in that age group. Finally, the number of patients experiencing dialysis or death in our study was low, limiting our ability to evaluate the association of biomarkers with these outcomes. 
CONCLUSIONS
